Review of Health Problems in Adult Patients with Classic Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency

 

 Permissions and Reprints

Abstract

The introduction of newborn screening programmes in most Western countries for classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency (CAH) enables timely introduction of life-saving glucocorticoid replacement in affected babies. Early diagnosis and optimised pediatric care not only successfully led to survival but also allow that almost all patients reach adulthood. Cohort studies in adults, however, provided evidence for significant health problems and co-morbidities of adult patients such as life-threatening adrenal crises, cardiovascular and metabolic health problems, fertility problems, benign endocrine tumours, and osteopenia and osteoporosis. This review summarises the current state of knowledge aiming to emphasize the neccessity of primary and secondary prevention of additional long-term health issues as a major task of health professionals in the care of CAH.

• References

• 1 El-Maouche D, Arlt W, Merke DP. Congenital adrenal hyperplasia. Lancet 2017; 390: 2194-2210. doi:10.1016/S0140-6736(17)31431-9
  CrossrefPubMedGoogle Scholar
• 2 Therrell BL, Adams J. Newborn screening in North America. J Inherit Metab Dis 2007; 30: 447-465
  CrossrefPubMedGoogle Scholar
• 3 Coulm B, Coste J, Tardy V. et al. Efficiency of neonatal screening for congenital adrenal hyperplasia due to 21-hydroxylase deficiency in children born in mainland France between 1996 and 2003. Arch Pediatr Adolesc Med 2012; 166: 113-120
  CrossrefPubMedGoogle Scholar
• 4 Odenwald B, Dorr HG, Bonfig W. et al. Classic congenital adrenal hyperplasia due to 21-hydroxylase-deficiency: 13 Years of neonatal screening and follow-up in bavaria. Klin Padiatr 2015; 227: 278-283. doi:10.1055/s-0035-1554639
  Article in Thieme ConnectPubMedGoogle Scholar
• 5 Carmina E, Dewailly D, Escobar-Morreale HF. et al. Non-classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency revisited: An update with a special focus on adolescent and adult women. Hum Reprod Update 2017; 23: 580-599. doi:10.1093/humupd/dmx014
  CrossrefPubMedGoogle Scholar
• 6 Falhammar H, Butwicka A, Landen M. et al. Increased psychiatric morbidity in men with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 2014; 99: E554-E560
  CrossrefPubMedGoogle Scholar
• 7 Falhammar H, Frisen L, Norrby C. et al. Increased mortality in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 2014; jc20142957
  PubMedGoogle Scholar
• 8 Rushworth RL, Torpy DJ, Falhammar H. Adrenal crises: Perspectives and research directions. Endocrine 2017; 55: 336-345. doi:10.1007/s12020-016-1204-2
  CrossrefPubMedGoogle Scholar
• 9 Odenwald B, Nennstiel-Ratzel U, Dorr HG. et al. Children with classic congenital adrenal hyperplasia experience salt loss and hypoglycemia: Evaluation of adrenal crises during the first 6 years of life. Eur J Endocrinol 2016; 174: 177-186. doi:10.1530/EJE-15-0775
  CrossrefPubMedGoogle Scholar
• 10 Kim MS, Ryabets-Lienhard A, Bali B. et al. Decreased adrenomedullary function in infants with classical congenital adrenal hyperplasia. J Clin Endocrinol Metab 2014; 99: E1597-E1601. doi:10.1210/jc.2014-1274
  CrossrefPubMedGoogle Scholar
• 11 Reisch N, Willige M, Kohn D. et al. Frequency and causes of adrenal crises over lifetime in patients with 21-hydroxylase deficiency. Eur J Endocrinol 2012; 167: 35-42
  CrossrefPubMedGoogle Scholar
• 12 Bancos I, Hazeldine J, Chortis V. et al. Primary adrenal insufficiency is associated with impaired natural killer cell function: A potential link to increased mortality. Eur J Endocrinol 2017; 176: 471-480. doi:10.1530/EJE-16-0969
  CrossrefPubMedGoogle Scholar
• 13 Isidori AM, Venneri MA, Graziadio C. et al. Effect of once-daily, modified-release hydrocortisone versus standard glucocorticoid therapy on metabolism and innate immunity in patients with adrenal insufficiency (DREAM): A single-blind, randomised controlled trial. Lancet Diabetes Endocrinol 2018; 6: 173-185. doi:10.1016/S2213-8587(17)30398-4
  CrossrefPubMedGoogle Scholar
• 14 Allolio B. Extensive expertise in endocrinology. Adrenal crisis. Eur J Endocrinol 2015; 172: R115-R124. doi:10.1530/EJE-14-0824
  PubMedGoogle Scholar
• 15 Hahner S, Hemmelmann N, Quinkler M. et al. Timelines in the management of adrenal crisis - targets, limits and reality. Clin Endocrinol (Oxf) 2015; 82: 497-502. doi:10.1111/cen.12609
  CrossrefPubMedGoogle Scholar
• 16 Hahner S, Spinnler C, Fassnacht M. et al. High incidence of adrenal crisis in educated patients with chronic adrenal insufficiency: A prospective study. J Clin Endocrinol Metab 2015; 100: 407-416. doi:10.1210/jc.2014-3191
  CrossrefPubMedGoogle Scholar
• 17 Mooij CF, van Herwaarden AE, Sweep F. et al. Cardiovascular and metabolic risk in pediatric patients with congenital adrenal hyperplasia due to 21 hydroxylase deficiency. J Pediatr Endocrinol Metab 2017; 30: 957-966. doi:10.1515/jpem-2017-0068
  PubMedGoogle Scholar
• 18 Sartorato P, Zulian E, Benedini S. et al. Cardiovascular risk factors and ultrasound evaluation of intima-media thickness at common carotids, carotid bulbs, and femoral and abdominal aorta arteries in patients with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 2007; 92: 1015-1018
  CrossrefPubMedGoogle Scholar
• 19 Bachelot A, Plu-Bureau G, Thibaud E. et al. Long-term outcome of patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Horm Res 2007; 67: 268-276
  CrossrefPubMedGoogle Scholar
• 20 Arlt W, Willis DS, Wild SH. et al. Health status of adults with congenital adrenal hyperplasia: A cohort study of 203 patients. J Clin Endocrinol Metab 2010; 95: 5110-5121
  CrossrefPubMedGoogle Scholar
• 21 Falhammar H, Filipsson H, Holmdahl G. et al. Metabolic profile and body composition in adult women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 2007; 92: 110-116
  CrossrefPubMedGoogle Scholar
• 22 Ozdemir R, Korkmaz HA, Kucuk M. et al. Assessment of early atherosclerosis and left ventricular dysfunction in children with 21-hydroxylase deficiency. Clin Endocrinol (Oxf) 2017; 86: 473-479. doi:10.1111/cen.13275
  CrossrefPubMedGoogle Scholar
• 23 Bachelot A, Golmard JL, Dulon J. et al. Determining clinical and biological indicators for health outcomes in adult patients with childhood onset of congenital adrenal hyperplasia. Eur J Endocrinol 2015; 173: 175-184. doi:10.1530/EJE-14-0978
  CrossrefPubMedGoogle Scholar
• 24 Finkielstain GP, Kim MS, Sinaii N. et al. Clinical characteristics of a cohort of 244 patients with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2012; 97: 4429-4438
  CrossrefPubMedGoogle Scholar
• 25 Volkl TM, Simm D, Beier C. et al. Obesity among children and adolescents with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Pediatrics 2006; 117: e98-e105
  CrossrefPubMedGoogle Scholar
• 26 Sarafoglou K, Forlenza GP, Yaw Addo O. et al. Obesity in children with congenital adrenal hyperplasia in the Minnesota cohort: Importance of adjusting body mass index for height-age. Clin Endocrinol (Oxf) 2017; 86: 708-716. doi:10.1111/cen.13313
  CrossrefPubMedGoogle Scholar
• 27 Bouvattier C, Esterle L, Renoult-Pierre P. et al. Clinical outcome, hormonal status, gonadotrope axis, and testicular function in 219 adult men born with classic 21-hydroxylase deficiency. a french national survey. J Clin Endocrinol Metab 2015; 100: 2303-2313. doi:10.1210/jc.2014-4124
  CrossrefPubMedGoogle Scholar
• 28 Kim MS, Ryabets-Lienhard A, Dao-Tran A. et al. Increased abdominal adiposity in adolescents and young adults with classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 2015; 100: E1153-E1159. doi:10.1210/jc.2014-4033
  CrossrefPubMedGoogle Scholar
• 29 Moreira RP, Villares SM, Madureira G. et al. Obesity and familial predisposition are significant determining factors of an adverse metabolic profile in young patients with congenital adrenal hyperplasia. Horm Res Paediatr 2013; 80: 111-118. doi:10.1159/000353762
  CrossrefPubMedGoogle Scholar
• 30 Mooij CF, Kroese JM, Claahsen-van der Grinten HL. et al. Unfavourable trends in cardiovascular and metabolic risk in paediatric and adult patients with congenital adrenal hyperplasia?. Clin Endocrinol (Oxf) 2010; 73: 137-146
  PubMedGoogle Scholar
• 31 Ubertini G, Bizzarri C, Grossi A. et al. Blood pressure and left ventricular characteristics in young patients with classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Int J Pediatr Endocrinol 2009; 2009: 383610. doi:10.1155/2009/383610
  CrossrefPubMedGoogle Scholar
• 32 Subbarayan A, Dattani MT, Peters CJ. et al. Cardiovascular risk factors in children and adolescents with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Clin Endocrinol (Oxf) 2014; 80: 471-477. doi:10.1111/cen.12265
  CrossrefPubMedGoogle Scholar
• 33 de Silva KS, Kanumakala S, Brown JJ. et al. 24-hour ambulatory blood pressure profile in patients with congenital adrenal hyperplasia–a preliminary report. J Pediatr Endocrinol Metab 2004; 17: 1089-1095
  PubMedGoogle Scholar
• 34 Volkl TM, Simm D, Dotsch J. et al. Altered 24-hour blood pressure profiles in children and adolescents with classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 2006; 91: 4888-4895
  CrossrefPubMedGoogle Scholar
• 35 Nermoen I, Bronstad I, Fougner KJ. et al. Genetic, anthropometric and metabolic features of adult Norwegian patients with 21-hydroxylase deficiency. Eur J Endocrinol 2012; 167: 507-516. doi:10.1530/EJE-12-0196
  CrossrefPubMedGoogle Scholar
• 36 Mooij CF, Kroese JM, Sweep FC. et al. Adult patients with congenital adrenal hyperplasia have elevated blood pressure but otherwise a normal cardiovascular risk profile. PLoS One 2011; 6: e24204. doi:10.1371/journal.pone.0024204
  CrossrefPubMedGoogle Scholar
• 37 Roche EF, Charmandari E, Dattani MT. et al. Blood pressure in children and adolescents with congenital adrenal hyperplasia (21-hydroxylase deficiency): A preliminary report. Clin Endocrinol (Oxf) 2003; 58: 589-596
  CrossrefPubMedGoogle Scholar
• 38 Jones CM, Mallappa A, Reisch N. et al. Modified-release and conventional glucocorticoids and diurnal androgen excretion in congenital adrenal hyperplasia. J Clin Endocrinol Metab 2017; 102: 1797-1806. doi:10.1210/jc.2016-2855
  PubMedGoogle Scholar
• 39 Mallappa A, Sinaii N, Kumar P. et al. A phase 2 study of Chronocort, a modified-release formulation of hydrocortisone, in the treatment of adults with classic congenital adrenal hyperplasia. J Clin Endocrinol Metab 2015; 100: 1137-1145 doi:10.1210/jc.2014-3809
  CrossrefPubMedGoogle Scholar
• 40 Quinkler M, Miodini Nilsen R, Zopf K. et al. Modified-release hydrocortisone decreases BMI and HbA1c in patients with primary and secondary adrenal insufficiency. Eur J Endocrinol 2015; 172: 619-626. doi:10.1530/EJE-14-1114
  CrossrefPubMedGoogle Scholar
• 41 Johannsson G, Nilsson AG, Bergthorsdottir R. et al. Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: A prospective randomized trial of a novel hydrocortisone dual-release formulation. J Clin Endocrinol Metab 2012; 97: 473-481. doi:10.1210/jc.2011-1926
  CrossrefPubMedGoogle Scholar
• 42 Fuller PJ, Young MJ. Mechanisms of mineralocorticoid action. Hypertension 2005; 46: 1227-1235. doi:10.1161/01.HYP.0000193502.77417.17
  CrossrefPubMedGoogle Scholar
• 43 Pivonello R, Isidori AM, De Martino MC. et al. Complications of Cushing’s syndrome: State of the art. Lancet Diabetes Endocrinol 2016; 4: 611-629. doi:10.1016/S2213-8587(16)00086-3
  CrossrefPubMedGoogle Scholar
• 44 Rosenfield RL, Ehrmann DA. The pathogenesis of polycystic ovary syndrome (pcos): The hypothesis of pcos as functional ovarian hyperandrogenism revisited. Endocr Rev 2016; 37: 467-520. doi:10.1210/er.2015-1104
  CrossrefPubMedGoogle Scholar
• 45 Saygili F, Oge A, Yilmaz C. Hyperinsulinemia and insulin insensitivity in women with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency: the relationship between serum leptin levels and chronic hyperinsulinemia. Horm Res 2005; 63: 270-274
  CrossrefPubMedGoogle Scholar
• 46 Falhammar H, Frisen L, Hirschberg AL. et al. Increased cardiovascular and metabolic morbidity in patients with 21-hydroxylase deficiency: a swedish population-based national cohort study. J Clin Endocrinol Metab 2015; 100: 3520-3528. doi:10.1210/JC.2015-2093
  CrossrefPubMedGoogle Scholar
• 47 Abehsira G, Bachelot A, Badilini F. et al. Complex influence of gonadotropins and sex steroid hormones on qt interval duration. J Clin Endocrinol Metab 2016; 101: 2776-2784. doi:10.1210/jc.2016-1877
  CrossrefPubMedGoogle Scholar
• 48 Falhammar H, Filipsson H, Holmdahl G. et al. Fractures and bone mineral density in adult women with 21-hydroxylase deficiency. J Clin Endocrinol Metab 2007; 92: 4643-4649
  CrossrefPubMedGoogle Scholar
• 49 Schulz J, Frey KR, Cooper MS. et al. Reduction in daily hydrocortisone dose improves bone health in primary adrenal insufficiency. Eur J Endocrinol 2016; 174: 531-538. doi:10.1530/EJE-15-1096
  CrossrefPubMedGoogle Scholar
• 50 Frey KR, Kienitz T, Schulz J. et al. Prednisolone is associated with a worse bone mineral density in primary adrenal insufficiency. Endocr Connect 2018; 7: 811-818. doi:10.1530/EC-18-0160
  CrossrefPubMedGoogle Scholar
• 51 Koetz KR, Ventz M, Diederich S. et al. Bone mineral density is not significantly reduced in adult patients on low-dose glucocorticoid replacement therapy. J Clin Endocrinol Metab 2012; 97: 85-92
  CrossrefPubMedGoogle Scholar
• 52 Reisch N, Flade L, Scherr M. et al. High prevalence of reduced fecundity in men with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2009; 94: 1665-1670
  CrossrefPubMedGoogle Scholar
• 53 Reisch N, Arlt W, Krone N. Health problems in congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Horm Res Paediatr 2011; 76: 73-85
  CrossrefPubMedGoogle Scholar
• 54 Engberg H, Butwicka A, Nordenstrom A. et al. Congenital adrenal hyperplasia and risk for psychiatric disorders in girls and women born between 1915 and 2010: A total population study. Psychoneuroendocrinology 2015; 60: 195-205. doi:10.1016/j.psyneuen.2015.06.017
  CrossrefPubMedGoogle Scholar
• 55 Ohlsson Gotby A, Nordenstrom A, Falhammar H. et al. Congenital adrenal hyperplasia, polycystic ovary syndrome and criminal behavior: A Swedish population based study. Psychiatry Res 2015; 229: 953-959. doi:10.1016/j.psychres.2015.07.008
  CrossrefPubMedGoogle Scholar
• 56 Nordenstrom A, Butwicka A, Linden Hirschberg A. et al. Are carriers of CYP21A2 mutations less vulnerable to psychological stress? A population-based national cohort study. Clin Endocrinol (Oxf) 2017; 86: 317-324. doi:10.1111/cen.13242
  CrossrefPubMedGoogle Scholar
• 57 Krone N, Wachter I, Stefanidou M. et al. Mothers with congenital adrenal hyperplasia and their children: Outcome of pregnancy, birth and childhood. Clin Endocrinol (Oxf) 2001; 55: 523-529
  CrossrefPubMedGoogle Scholar
• 58 Lo JC, Grumbach MM. Pregnancy outcomes in women with congenital virilizing adrenal hyperplasia. Endocrinol Metab Clin North Am 2001; 30: 207-229
  CrossrefPubMedGoogle Scholar
• 59 Gastaud F, Bouvattier C, Duranteau L. et al. Impaired sexual and reproductive outcomes in women with classical forms of congenital adrenal hyperplasia. J Clin Endocrinol Metab 2007; 92: 1391-1396
  CrossrefPubMedGoogle Scholar
• 60 Jaaskelainen J, Hippelainen M, Kiekara O. et al. Child rate, pregnancy outcome and ovarian function in females with classical 21-hydroxylase deficiency. Acta Obstet Gynecol Scand 2000; 79: 687-692
  PubMedGoogle Scholar
• 61 Hagenfeldt K, Janson PO, Holmdahl G. et al. Fertility and pregnancy outcome in women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Hum Reprod 2008; 23: 1607-1613
  CrossrefPubMedGoogle Scholar
• 62 Hoepffner W, Schulze E, Bennek J. et al. Pregnancies in patients with congenital adrenal hyperplasia with complete or almost complete impairment of 21-hydroxylase activity. Fertil Steril 2004; 81: 1314-1321
  CrossrefPubMedGoogle Scholar
• 63 Bachelot A, Chakhtoura Z, Plu-Bureau G. et al. Influence of hormonal control on LH pulsatility and secretion in women with classical congenital adrenal hyperplasia. Eur J Endocrinol 2012; 167: 499-505. doi:10.1530/EJE-12-0454
  CrossrefPubMedGoogle Scholar
• 64 Moran C, Azziz R, Weintrob N. et al. Reproductive outcome of women with 21-hydroxylase-deficient nonclassic adrenal hyperplasia. J Clin Endocrinol Metab 2006; 91: 3451-3456
  CrossrefPubMedGoogle Scholar
• 65 Bidet M, Bellanne-Chantelot C, Galand-Portier MB. et al. Fertility in women with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 2010; 95: 1182-1190
  CrossrefPubMedGoogle Scholar
• 66 Casteras A, De Silva P, Rumsby G. et al. Reassessing fecundity in women with classical congenital adrenal hyperplasia (CAH): Normal pregnancy rate but reduced fertility rate. Clin Endocrinol (Oxf) 2009; 70: 833-837
  CrossrefPubMedGoogle Scholar
• 67 Holmes-Walker DJ, Conway GS, Honour JW. et al. Menstrual disturbance and hypersecretion of progesterone in women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Clin Endocrinol (Oxf) 1995; 43: 291-296
  CrossrefPubMedGoogle Scholar
• 68 Ogilvie CM, Rumsby G, Kurzawinski T. et al. Outcome of bilateral adrenalectomy in congenital adrenal hyperplasia: One unit’s experience. Eur J Endocrinol 2006; 154: 405-408
  CrossrefPubMedGoogle Scholar
• 69 Meyer-Bahlburg HF, Dolezal C, Baker SW. et al. Sexual orientation in women with classical or non-classical congenital adrenal hyperplasia as a function of degree of prenatal androgen excess. Arch Sex Behav 2008; 37: 85-99
  CrossrefPubMedGoogle Scholar
• 70 Wang LC, Poppas DP. Surgical outcomes and complications of reconstructive surgery in the female congenital adrenal hyperplasia patient: What every endocrinologist should know. J Steroid Biochem Mol Biol 2017; 165: 137-144. doi:10.1016/j.jsbmb.2016.03.021
  CrossrefPubMedGoogle Scholar
• 71 Sturm RM, Durbin-Johnson B, Kurzrock EA. Congenital adrenal hyperplasia: current surgical management at academic medical centers in the United States. J Urol 2015; 193: 1796-1801. doi:10.1016/j.juro.2014.11.008
  CrossrefPubMedGoogle Scholar
• 72 Mouriquand PD, Gorduza DB, Gay CL. et al. Surgery in disorders of sex development (DSD) with a gender issue: If (why), when, and how?. J Pediatr Urol 2016; 12: 139-149. doi:10.1016/j.jpurol.2016.04.001
  CrossrefPubMedGoogle Scholar
• 73 Reifsnyder JE, Stites J, Bernabe KJ. et al. Nerve Sparing Clitoroplasty is an Option for Adolescent and Adult Female Patients with Congenital Adrenal Hyperplasia and Clitoral Pain following Prior Clitoral Recession or Incomplete Reduction. J Urol 2016; 195: 1270-1273. doi:10.1016/j.juro.2015.12.053
  CrossrefPubMedGoogle Scholar
• 74 Lesma A, Bocciardi A, Montorsi F. et al. Passerini-glazel feminizing genitoplasty: Modifications in 17 years of experience with 82 cases. Eur Urol 2007; 52: 1638-1644. doi:10.1016/j.eururo.2007.02.068
  CrossrefPubMedGoogle Scholar
• 75 Nordenstrom A, Frisen L, Falhammar H. et al. Sexual function and surgical outcome in women with congenital adrenal hyperplasia due to CYP21A2 deficiency: Clinical perspective and the patients’ perception. J Clin Endocrinol Metab 2010; 95: 3633-3640
  CrossrefPubMedGoogle Scholar
• 76 Claahsen-van der Grinten HL, Hulsbergen-van de Kaa CA, Otten BJ. Ovarian adrenal rest tissue in congenital adrenal hyperplasia–a patient report. J Pediatr Endocrinol Metab 2006; 19: 177-182
  PubMedGoogle Scholar
• 77 Motlik K, Starka L. Adrenocortical tumour of the ovary. (A case report with particular stress upon morphological and biochemical findings). Neoplasma 1973; 20: 97-110
  PubMedGoogle Scholar
• 78 Russo G, Paesano P, Taccagni G. et al. Ovarian adrenal-like tissue in congenital adrenal hyperplasia. N Engl J Med 1998; 339: 853-854
  CrossrefPubMedGoogle Scholar
• 79 Luton JP, Clerc J, Paoli V. et al. [Bilateral Leydig cell tumor of the ovary in a woman with congenital adrenal hyperplasia. The first reported case]. Presse Med 1991; 20: 109-112
  PubMedGoogle Scholar
• 80 Cabrera MS, Vogiatzi MG, New MI. Long term outcome in adult males with classic congenital adrenal hyperplasia. J Clin Endocrinol Metab 2001; 86: 3070-3078
  PubMedGoogle Scholar
• 81 Stikkelbroeck NM, Otten BJ, Pasic A. et al. High prevalence of testicular adrenal rest tumors, impaired spermatogenesis, and Leydig cell failure in adolescent and adult males with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2001; 86: 5721-5728
  CrossrefPubMedGoogle Scholar
• 82 Martinez-Aguayo A, Rocha A, Rojas N. et al. Testicular adrenal rest tumors and Leydig and Sertoli cell function in boys with classical congenital adrenal hyperplasia. J Clin Endocrinol Metab 2007; 92: 4583-4589
  CrossrefPubMedGoogle Scholar
• 83 Claahsen-van der Grinten HL, Sweep FC, Blickman JG. et al. Prevalence of testicular adrenal rest tumours in male children with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Eur J Endocrinol 2007; 157: 339-344
  CrossrefPubMedGoogle Scholar
• 84 Claahsen-van der Grinten HL, Otten BJ, Sweep FC. et al. Repeated successful induction of fertility after replacing hydrocortisone with dexamethasone in a patient with congenital adrenal hyperplasia and testicular adrenal rest tumors. Fertil Steril 2007; 88: 705 e705-705 e708
  PubMedGoogle Scholar
• 85 Claahsen-van der Grinten HL, Otten BJ, Stikkelbroeck MM. et al. Testicular adrenal rest tumours in congenital adrenal hyperplasia. Best Pract Res Clin Endocrinol Metab 2009; 23: 209-220
  CrossrefPubMedGoogle Scholar
• 86 Reisch N, Scherr M, Flade L. et al. Total adrenal volume but not testicular adrenal rest tumor volume is associated with hormonal control in patients with 21-hydroxylase deficiency. J Clin Endocrinol Metab 2010; 95: 2065-2072
  CrossrefPubMedGoogle Scholar
• 87 Smeets EE, Span PN, van Herwaarden AE. et al. Molecular characterization of testicular adrenal rest tumors in congenital adrenal hyperplasia: Lesions with both adrenocortical and Leydig cell features. J Clin Endocrinol Metab 2015; 100: E524-E530. doi:10.1210/jc.2014-2036
  CrossrefPubMedGoogle Scholar
• 88 Claahsen-van der Grinten HL, Otten BJ, Hermus AR. et al. Testicular adrenal rest tumors in patients with congenital adrenal hyperplasia can cause severe testicular damage. Fertil Steril 2007; 92: 3674-3680
  PubMedGoogle Scholar
• 89 Bry-Gauillard H, Cartes A, Young J. Mitotane for 21-hydroxylase deficiency in an infertile man. N Engl J Med 2014; 371: 2042-2044. doi:10.1056/NEJMc1410041
  PubMedGoogle Scholar
• 90 Rohayem J, Tuttelmann F, Mallidis C. et al. Restoration of fertility by gonadotropin replacement in a man with hypogonadotropic azoospermia and testicular adrenal rest tumors due to untreated simple virilizing congenital adrenal hyperplasia. Eur J Endocrinol 2014; 170: K11-K17. doi:10.1530/EJE-13-0449
  CrossrefPubMedGoogle Scholar
• 91 King TF, Lee MC, Williamson EE. et al. Experience in optimizing fertility outcomes in men with congenital adrenal hyperplasia due to 21 hydroxylase deficiency. Clin Endocrinol (Oxf) 2016; 84: 830-836. doi:10.1111/cen.13001
  CrossrefPubMedGoogle Scholar
• 92 Turcu AF, Mallappa A, Elman MS. et al. 11-Oxygenated Androgens Are Biomarkers of Adrenal Volume and Testicular Adrenal Rest Tumors in 21-Hydroxylase Deficiency. J Clin Endocrinol Metab 2017; 102: 2701-2710. doi:10.1210/jc.2016-3989
  CrossrefPubMedGoogle Scholar
• 93 Nermoen I, Rorvik J, Holmedal SH. et al. High frequency of adrenal myelolipomas and testicular adrenal rest tumours in adult Norwegian patients with classical congenital adrenal hyperplasia because of 21-hydroxylase deficiency. Clin Endocrinol (Oxf) 2011; 75: 753-759
  CrossrefPubMedGoogle Scholar